Skip to main content

Advertisement

Table 1 Baseline patient and caregiver characteristics

From: Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study

Characteristic EXPEDITION RCTs (EU population) GERAS observational study p value for unadjusted baseline comparison
Patients, N 168 566  
 Age (years) 71.9 (7.4) 77.3 (6.9) < 0.001
 Sex (female), n (%) 85 (50.6) 271 (47.9) 0.83
 Patient education (years) 11.6 (3.9) 11.1 (3.3) 0.06
 Time since AD diagnosis (years) 1.7 (1.5) 1.7 (2.0) 0.90
 AD treatment category, n (%)    < 0.001
  AChEI only 129 (76.8) 411 (72.6)  
  Memantine only 12 (7.1) 41 (7.2)  
  AChEI + memantine 19 (11.3) 26 (4.6)  
  No AD treatment 8 (4.8) 88 (15.5)  
 MMSE score 23.1 (2.0) 23.3 (1.6) 0.15
Caregivers, N 168 566  
 Age (years) 64.2 (12.2) 68.1 (11.6) < 0.001
 Sex (female), n (%) 101 (60.5) 387 (68.5) 0.21
 Caregiver is patient’s spouse, n (%) 116 (69.5) 399 (70.6) 0.82
 Caregiver is working for pay, n (%) 57 (34.1) 133 (23.5) 0.04
  1. Data presented as mean (standard deviation) unless otherwise indicated. Percentages based on the number of patients/caregivers with available data (missing data ranged from zero to one participant in the EXPEDITION trials and from zero to three participants in the GERAS study). p-values in bold represent a significant difference between EXPEDITION and GERAS
  2. AChEI acetylcholinesterase inhibitor, AD Alzheimer’s disease, EU European, MMSE Mini-Mental State Examination, RCT randomised controlled trial